Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5052W HIGH $10.14
Volume
88.78 K
Value Traded
352.33 K
Short % Float
2.27%
Days to Cover
2.8
+1.54%Week
-4.13%1 Month
+4.25%3 Month
+25.26%6 Month
-98.92%5 Year
-98.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
186.85 M
EPS (TTM)
-1.08
P/E Ratio
-
Ent. Value
145.47 M
Total Shares
21.77 M
Float Shares
14.23 M
Insiders
8.37%
Institutions
82.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ACOG Catalyst Timeline
Dated clinical, regulatory and corporate events for Alpha Cognition Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alpha Cognition Inc.
75Total events
12Upcoming
9Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Composition Patent FiledbenzgalantamineApprovedIP / Competition
USPTO publishes U.S. Patent Application No. 19/090,242 for benzgalantamine manufacturing process
▲RWE DataZUNVEYLApprovedClinical Data
Initial CONVERGE real-world evidence results for ZUNVEYL in long-term care
mild to moderate dementia of the Alzheimer's typesource ↗
▲Enrollment CompleteZUNVEYLApprovedTrial
BEACON enrollment substantially complete
Alzheimer's diseasesource ↗
●Quarterly UpdateCorporate
Alpha Cognition to report Q2 2026 financial results and provide business update
●Quarterly UpdateZUNVEYLApprovedCorporate
Alpha Cognition reports Q2 2026 financial results and operational update
mild to moderate dementia of the Alzheimer's typesource ↗
▲Patent GrantedZUNVEYLApprovedIP / Competition
European Patent Office grants patent covering crystalline solid form of benzgalantamine for ZUNVEYL
mild-to-moderate Alzheimer's diseasesource ↗
◆Topline ReadoutZUNVEYLApprovedClinical Data
Topline data for BEACON anticipated in early Q3 2026
Alzheimer's diseasesource ↗
◆Timing GuidanceZUNVEYLApprovedPresentation
CONVERGE topline data expected in Q3 2026
Alzheimer's disease (long-term care tolerability, dosing, polypharmacy, adverse events)source ↗
▲First Patient DosedZUNVEYLApprovedTrial
First patient enrolled in RESOLVE Phase 4 study of ZUNVEYL
Mild to Moderate Alzheimer’s Diseasesource ↗
▲Topline ReadoutZUNVEYLApprovedClinical Data
Positive top-line results from BEACON real-world study of ZUNVEYL in Alzheimer's Disease
Alzheimer's Diseasesource ↗
●Oral PresentationZUNVEYLApprovedPresentation
Presenting at NEI Spring Congress in May 2026
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Craig Hallum's 23rd Annual Institutional Investor Conference 1x1 meetings
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq fireside chat and 1x1 meetings
●Quarterly UpdateZUNVEYLApprovedCorporate
Q1 2026 financial results reported
Alzheimer's diseasesource ↗
●Oral PresentationZUNVEYLApprovedPresentation
Presenting at NEI Spring Congress
Alzheimer's diseasesource ↗
●Oral PresentationZUNVEYLApprovedPresentation
Presented new clinical data at AAGP in April 2026
Alzheimer's diseasesource ↗
●Oral PresentationZUNVEYLApprovedPresentation
Presented new clinical data at AAGP
Alzheimer's diseasesource ↗
●Trial InitiationZUNVEYLApprovedTrial
Initiation of CONVERGE, a 400-patient retrospective data analysis in long-term care
Alzheimer's disease (long-term care tolerability, dosing, polypharmacy, adverse events)source ↗
●Trial InitiationALPHA-1062FiledTrial
Comparative PK study for sublingual formulation expected to initiate in Q2 2026
Alzheimer's diseasesource ↗
▲Patent GrantedALPHA-1062FiledIP / Competition
USPTO issued patent covering use of ALPHA-1062 for treating traumatic brain injury
traumatic brain injurysource ↗
●Quarterly UpdateZUNVEYLApprovedCorporate
Cash and cash equivalents totaled $54.2 million as of March 31, 2026
Alzheimer's diseasesource ↗
●Quarterly UpdateCorporate
Reports Fiscal 2025 Financial Results and Provides Operational Update
▲Patent GrantedALPHA-1062FiledIP / Competition
USPTO issued patent covering use of ALPHA-1062 for treating traumatic brain injury
traumatic brain injurysource ↗
▲First Patient DosedZUNVEYLApprovedTrial
First patient enrolled in BEACON real-world effectiveness study
Alzheimer's diseasesource ↗
▲Patent GrantedZUNVEYLApprovedIP / Competition
USPTO issued patent covering dosing regimens for benzgalantamine (ZUNVEYL)
mild to moderate Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Alpha Cognition to participate in virtual fireside chat hosted by Titan Partners
▲Quarterly UpdateZUNVEYLApprovedCorporate
Q4 2025 bottles dispensed increased 62% quarter-over-quarter to 4,941
Alzheimer's diseasesource ↗
◆Product LaunchZUNVEYLApprovedPost-Market
ZUNVEYL expected to be available by prescription in pharmacies nationwide
mild-to-moderate Alzheimer's diseasesource ↗
▲Partnership / LicenseZUNVEYLApprovedCorporate
Executed second national PBM contract
Alzheimer's diseasesource ↗
◆Product LaunchZUNVEYLApprovedPost-Market
Preparation for commercial launch of ZUNVEYL
Alzheimer's diseasesource ↗
▲FDA ApprovalZUNVEYLApprovedFDA Decision
FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease
mild-to-moderate Alzheimer's diseasesource ↗
◆PDUFA DateALPHA-1062FiledRegulatory Filing
PDUFA date for ALPHA-1062
mild-to-moderate Alzheimer's diseasesource ↗
●Composition Patent FiledALPHA-1062FiledIP / Competition
New composition of matter patent filed for ALPHA-1062
▲FDA Filing AcceptedALPHA-1062FiledRegulatory Filing
NDA for ALPHA-1062 accepted for review by FDA
mild-to-moderate Alzheimer's diseasesource ↗
▼Equity OfferingCorporate
Withdrawal of marketed public offering announced on November 17, 2022
●Timing GuidanceALPHA-1062FiledPresentation
Expected 505(b)(2) NDA submission for ALPHA-1062
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How ACOG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-07-26 | Zunveyl (benzgalantamine gluconate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ZUNVEYL |
Clinical Trial Results
Readouts, endpoints and source filings for every ACOG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% Owner | Buy | 14,283 3,259,894 held | $8.23 | 10/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACOG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 1.9 % | 20.91 M | 2.90 M | 13.02% ( 333.52 K) |
ACOG Institutional Ownership Trends
ACOG Short Interest
Shares sold short, counted twice a month.
2.27%
Short % of Float
of tradable shares sold short
323.4K
Shares Sold Short
+54.6% vs prior count
2.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
115.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACOG ranks across every disease it competes in
Competitive Position is a premium feature
See how ACOG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACOG News
-ACOG
Oct 13, 2026Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®
Alpha Cognition Inc. announced the publication of U.S. Patent Application No. 19/090,242, which details a proprietary manufacturing process for benzgalantamine, the active ingredient in ZUNVEYL®. This innovation aims to enhance manufacturing efficiency and product quality. CEO Michael McFadden emphasized the importance of these advancements for the long-term commercial potential of ZUNVEYL® and related programs.
Read more →-ACOG
Oct 6, 2026Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Alpha Cognition Inc. announced the presentation of new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors at the ASCP Annual Meeting. This event is scheduled for October 29 to November 1, 2026. The focus on neurodegenerative diseases underscores the company's commitment to advancing treatment options.
Read more →-ACOG
Oct 2, 2026Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Inc. has announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4). On October 1, 2026, the Compensation Committee approved nonstatutory stock options for 6,000 shares of common stock. This move reflects the company's commitment to attracting talent as it develops therapeutics for neurodegenerative disorders.
Read more →-ACOG
Oct 1, 2026Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Alpha Cognition Inc. has announced initial results from its CONVERGE study, which evaluates the use of ZUNVEYL (benzgalantamine) in long-term care settings. The study focuses on 180-day titration and medication patterns among residents. This real-world evidence aims to provide insights into the effectiveness and management of ZUNVEYL in a practical context.
Read more →-ACOG
Aug 13, 2026Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. reported its financial results for the second quarter of 2026, highlighting the ongoing commercial success of its therapeutic ZUNVEYL. The company expressed satisfaction with the adoption rates and provided updates on its operational activities. CEO Michael McFadden emphasized the positive trajectory of the business during this period.
Read more →-ACOG
Aug 3, 2026Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
Alpha Cognition Inc. has announced its plans to report second quarter 2026 financial results and provide a business update. The announcement is scheduled for August 13, 2026, at 4:30 p.m. ET, following market close. A press release will detail the financial results and business highlights on that date.
Read more →-ACOG
Jul 29, 2026Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
Alpha Cognition Inc. has received a patent from the European Patent Office for a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL. This patent is significant for the treatment of mild-to-moderate Alzheimer's disease. The development marks a positive step for the biopharmaceutical company in addressing neurodegenerative disorders.
Read more →-ACOG
Jul 10, 2026Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
Alpha Cognition Inc. will have its CEO, Michael McFadden, participate in a panel discussion at the B. Riley Securities Mind, Muscle & Vision Summit. This event is scheduled for July 16th in Boston, Massachusetts, and focuses on late-stage and commercial CNS therapies. The participation highlights Alpha Cognition's commitment to addressing neurodegenerative disorders.
Read more →-ACOG
Jun 23, 2026Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition has announced the election of Dr. Robert Wills as the new Chairman of the Board. This leadership change is expected to influence the company's strategic direction. Further details regarding Dr. Wills' vision for the company were not disclosed in the announcement.
Read more →-ACOG
Jun 16, 2026Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
Alpha Cognition has announced the enrollment of the first patient in its RESOLVE Phase 4 study. This study aims to evaluate the efficacy of ZUNVEYL® in patients diagnosed with mild to moderate Alzheimer's disease. The trial represents a significant step in exploring new treatment options for this patient population.
Read more →-ACOG
Jun 9, 2026Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
Alpha Cognition has announced positive top-line results from the BEACON real-world study of ZUNVEYL® in Alzheimer's Disease. The findings suggest that ZUNVEYL® may be effective in addressing symptoms associated with this condition. This development marks a significant step forward for the company in its efforts to provide solutions for Alzheimer's patients.
Read more →-ACOG
May 14, 2026Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. has released its financial results for the first quarter of 2026 and provided an operational update. However, the article lacks specific details regarding the financial performance or operational changes. The information presented does not indicate any significant positive or negative developments.
Read more →-ACOG
Apr 28, 2026Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
Alpha Cognition Inc. will report its first quarter 2026 financial results and provide a business update on May 14, 2026. A press release detailing these results will be available on their website, followed by a conference call for management to discuss the outcomes. The company focuses on treatments for neurodegenerative diseases, including Alzheimer's.
Read more →-ACOG
Apr 27, 2026▼ -6.2%on this newsshared move
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Alpha Cognition Inc. announced its participation in three upcoming investor conferences in May, with CEO Michael McFadden presenting. The events include the Market Movers Investor Summit, H.C. Wainwright BioConnect Conference, and Craig Hallum's Institutional Investor Conference. The company is focused on developing treatments for neurodegenerative diseases, including its drug ZUNVEYL for Alzheimer's.
Read more →-ACOG
Apr 20, 2026Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
Alpha Cognition has announced the appointment of Bethany Sensenig to its Board of Directors. This move is part of the company's strategy to strengthen its leadership team. Details about Sensenig's background and her expected contributions to the company were not provided in the announcement.
Read more →-ACOG
Apr 16, 2026Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 15, 2026
Alpha Cognition Inc. announced the grant of stock options to a new employee under its 2026 Inducement Grant Plan. The Compensation Committee approved the grant as part of the company's strategy to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4). Each stock option will vest over three years, aligning with the company's commitment to developing treatments for neurodegenerative diseases.
Read more →-ACOG
Apr 1, 2026▲ +8.6%on this news· ran to +27% by day 3
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
Alpha Cognition Inc. has received a U.S. patent for ALPHA-1062, aimed at treating traumatic brain injury (TBI). This patent, effective until 2045, bolsters the company's intellectual property and supports its strategy to expand beyond Alzheimer's disease. The TBI market presents a significant opportunity, with no approved therapies currently available.
Read more →About Alpha Cognition Inc.
Headquarters1452 HUGHES RD., STE. 200, GRAPEVINE, TX, 76051
BIOPHARMAWATCH ELITE PLUS
Trade the next ACOG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime